237 related articles for article (PubMed ID: 2585020)
41. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
Hagenbeek A; Carde P; Meerwaldt JH; Somers R; Thomas J; De Bock R; Raemaekers JM; van Hoof A; De Wolf-Peeters C; van Glabbeke M
J Clin Oncol; 1998 Jan; 16(1):41-7. PubMed ID: 9440721
[TBL] [Abstract][Full Text] [Related]
42. Diffuse aggressive lymphoma.
Fisher RI; Miller TP; O'Connor OA
Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
[TBL] [Abstract][Full Text] [Related]
43. Pleural effusion in patients with non-Hodgkin's lymphoma: a case-controlled study.
Elis A; Blickstein D; Mulchanov I; Manor Y; Radnay J; Shapiro H; Lishner M
Cancer; 1998 Oct; 83(8):1607-11. PubMed ID: 9781955
[TBL] [Abstract][Full Text] [Related]
44. Ki-1 antigen expression defines a favorable clinical subset of non-B cell non-Hodgkin's lymphoma.
Offit K; Ladanyi M; Gangi MD; Ebrahim SA; Filippa D; Chaganti RS
Leukemia; 1990 Sep; 4(9):625-30. PubMed ID: 2168505
[TBL] [Abstract][Full Text] [Related]
45. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
46. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
[TBL] [Abstract][Full Text] [Related]
47. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.
Martelli M; Gherlinzoni F; De Renzo A; Zinzani PL; De Vivo A; Cantonetti M; Falini B; Storti S; Meloni G; Rizzo M; Molinari AL; Lauria F; Moretti L; Lauta VM; Mazza P; Guardigni L; Pescarmona E; Pileri SA; Mandelli F; Tura S
J Clin Oncol; 2003 Apr; 21(7):1255-62. PubMed ID: 12663712
[TBL] [Abstract][Full Text] [Related]
48. [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
Qin Y; Shi YK; He XH; Yang JL; Yang S; Yu YX; Li B; Wang QL; Zhou LQ; Sun Y
Ai Zheng; 2006 Apr; 25(4):481-5. PubMed ID: 16613685
[TBL] [Abstract][Full Text] [Related]
49. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
Sonneveld P; de Ridder M; van der Lelie H; Nieuwenhuis K; Schouten H; Mulder A; van Reijswoud I; Hop W; Lowenberg B
J Clin Oncol; 1995 Oct; 13(10):2530-9. PubMed ID: 7595704
[TBL] [Abstract][Full Text] [Related]
50. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte.
Mounier N; Gisselbrecht C; Brière J; Haioun C; Feugier P; Offner F; Recher C; Stamatoullas A; Morschhauser F; Macro M; Thieblemont C; Sonet A; Fabiani B; Reyes F;
J Clin Oncol; 2004 Jul; 22(14):2826-34. PubMed ID: 15254050
[TBL] [Abstract][Full Text] [Related]
51. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis.
Gómez H; Hidalgo M; Casanova L; Colomer R; Pen DL; Otero J; Rodríguez W; Carracedo C; Cortés-Funes H; Vallejos C
J Clin Oncol; 1998 Jun; 16(6):2065-9. PubMed ID: 9626205
[TBL] [Abstract][Full Text] [Related]
52. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
53. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V
Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723
[TBL] [Abstract][Full Text] [Related]
54. Importance of cell surface marker to the prognosis of non-Hodgkin's lymphoma.
Toki H; Okabe K; Kamei H; Segawa Y; Koike S
Acta Med Okayama; 1988 Oct; 42(5):287-92. PubMed ID: 3265575
[TBL] [Abstract][Full Text] [Related]
55. The pathologic and clinical heterogeneity of lymphocyte-depleted Hodgkin's disease.
Kant JA; Hubbard SM; Longo DL; Simon RM; DeVita VT; Jaffe ES
J Clin Oncol; 1986 Mar; 4(3):284-94. PubMed ID: 3754003
[TBL] [Abstract][Full Text] [Related]
56. Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades--should peripheral T-cell lymphoma be considered separately?
Cheng AL; Chen YC; Wang CH; Su IJ; Hsieh HC; Chang JY; Hwang WS; Su WC; Liu TW; Tien HF
J Clin Oncol; 1989 Jun; 7(6):725-31. PubMed ID: 2654330
[TBL] [Abstract][Full Text] [Related]
57. Diffuse small cleaved-cell lymphoma: a heterogeneous disease with distinct immunobiologic subsets.
Leith CP; Spier CM; Grogan TM; Gonzales G; Rangel CS; Rybski JA; Matzner M; Miller TP
J Clin Oncol; 1992 Aug; 10(8):1259-65. PubMed ID: 1634915
[TBL] [Abstract][Full Text] [Related]
58. [Ki-1 non-Hodgkin's lymphoma. A multihospital study of 21 cases].
Rivas C; Obeso G; Piris M; Castrillo JM; Bellas C; Acevedo A; Martín C; Campo E; Gamallo C; Font M
Rev Clin Esp; 1989 Mar; 184(5):238-44. PubMed ID: 2549584
[TBL] [Abstract][Full Text] [Related]
59. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).
Gisselbrecht C; Gaulard P; Lepage E; Coiffier B; Brière J; Haioun C; Cazals-Hatem D; Bosly A; Xerri L; Tilly H; Berger F; Bouhabdallah R; Diebold J
Blood; 1998 Jul; 92(1):76-82. PubMed ID: 9639502
[TBL] [Abstract][Full Text] [Related]
60. t(9;14)(p13;q32) denotes a subset of low-grade non-Hodgkin's lymphoma with plasmacytoid differentiation.
Offit K; Parsa NZ; Filippa D; Jhanwar SC; Chaganti RS
Blood; 1992 Nov; 80(10):2594-9. PubMed ID: 1384792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
